Background: No data exist regarding the safety and effectiveness of a potassium replacement protocol for hospitalized patients when potassium replacement dosing regimens (KRDRs) are adjusted to Modification of Diet in Renal Disease estimation of glomerular filtration rate (MDRD GFR).
Objective: To evaluate the effectiveness and safety of a potassium replacement protocol in which KRDRs are prescribed based on MDRD GFR and serum potassium deficiency (Kdef).
Methods: Patients prescribed the potassium replacement order set were identified in a retrospective fashion. Serum potassium, prescriber-defined goal serum potassium, and MDRD GFR data were collected for patients who received protocol KRDRs. The KRDR to be administered is selected based on Kdef (goal serum potassium minus measured serum potassium) of 0.1-0.2, 0.3-0.5, or more than 0.5 mEq/L and the patients' MDRD GFR of greater than 70, 40-70, or less than 40 mL/min/1.73 m(2) (any patient undergoing dialysis is included in the <40 mL/min/1.73 m(2) group). Efficacy was evaluated by determining the change in serum potassium level (Delta K) following potassium replacement, the number of KRDRs needed to achieve goal serum potassium, and the milliequivalents of potassium needed to achieve goal serum potassium levels. Safety was assessed by the incidence of serum potassium values greater than 5.0 mEq/L following replacement.
Results: One hundred forty-nine patients were evaluated. There were 184 protocol initiations and 257 KRDRs administered to achieve goal serum potassium levels. The DeltaK was 0.50 +/- 0.40 mEq/L (mean +/- SD) following KRDR. The Delta K was similar between MDRD GFR groups. One hundred thirty six (73.9%) protocol initiations required 1 KRDR, and 168 (91.3%) protocol initiations required 1 or 2 KRDRs to achieve goal serum potassium. Patients whose MDRD GFR was 40-70 mL/min/1.73 m(2) were less likely to achieve goal serum potassium value after 1 KRDR (58.2% vs 79.6% >70 group and 84.6% <40 group). This was true regardless of the patient's goal serum potassium. One (0.54%) serum potassium greater than 5.0 mEq/L occurred following a KRDR.
Conclusions: Our potassium replacement protocol based on MDRD GFR and Kdef effectively corrects hypokalemia. Fewer protocol initiations achieved goal serum potassium levels in the group with MDRD GFR 40-70 mL/min/1.73 m(2). Hyperkalemia rarely occurred following KRDR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1345/aph.1L188 | DOI Listing |
J Clin Med
December 2024
Cardiology Department, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain.
: Hyperkalemia is a common electrolyte disorder in patients with heart failure and reduced ejection fraction (HFrEF). Renin-angiotensin-aldosterone system inhibitors (RAASi) have been shown to improve survival and decrease hospitalization rates, although they may increase the serum potassium levels. Hyperkalemia has significant clinical and economic implications, and is associated with increased healthcare resource utilization.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
January 2025
Department of Internal Medicine, Division of Nephrology and Hypertension, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia.
Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin- angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors, are effective in slowing CKD progression. However, these approaches are insufficient to comprehensively inhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significant driver of inflammation, fibrosis, and oxidative stress.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Nephrology, China-Japan Friendship Hospital, Beijing, China.
Background: Adjusting dietary potassium intake based on 24-hour urinary potassium excretion is the primary method of preventing hyperkalemia. Currently, there is no accurate and convenient method for calculating maximum 24-hour urinary potassium excretion in kidney failure without replacement therapy patients. We developed and validated two new models to assess the upper limit of dietary potassium consumption in this high-risk cohort, using the maximum 24-hour urinary potassium excretion as a proxy.
View Article and Find Full Text PDFClin Oral Investig
January 2025
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Objectives: To compare the impact of intaglio surface treatments - airborne particle abrasion and hydrofluoric acid (HF) etching - of feldspar ceramic (FEL) crowns on the fracture load (FL) and to investigate the effects of abutment materials and artificial aging. The aim was to assess whether etching could be replaced by an alternative surface roughening method.
Materials And Methods: FEL crowns had their intaglio surfaces either abraded (25 µm AlO, 0.
J Cardiothorac Surg
January 2025
Department of Anesthesiology, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, No. 123, Tianfei Lane, Mochou Road, Nanjing, Jiangsu, 210004, China.
Introduction: The study was to assess the myocardial protection effects of the histidine-tryptophan-ketoglutarate (HTK) solution and the 4:1 blood cardioplegia (BC) in patients with atrial fibrillation (AF) who were subjected to valvular replacement concomitant with the Cox maze III surgery.
Methods: A cohort of 148 individuals afflicted with AF, who received valve replacement surgery in conjunction with the Cox maze III procedure at our clinic within the period extending from 2015 to 2023, were enrolled. Subsequent to adjustment by propensity score matching (PSM), the patients were categorized into two distinct groups: the HTK group and the BC group.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!